Search

Paltusotine

[A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]

Amlexanox

Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. … Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.

DL-dimyristoylphosphatidylglycerol

DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

Fencamfamin

Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … It is especially useful in patients with chronic conditions due to its favourable safety profile.

Tolevamer

It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. … It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV.

Aluminium phosphate

Pyrophosphoric acid

Oxethazaine

Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at … [A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.

Magnesium gluconate

Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids … In addition, it has been studied for its effects on premature uterine contractions [A32808].

Marnetegragene autotemcel

[L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115] … [L56116, A275467] Marnetegragene autotemcel, also known as marne-cel, is an autologous hematopoietic stem cell-based gene therapy created from the patient's own hematopoietic stem cells.